Fenofibrate reduces cardiac remodeling and improves cardiac function in a rat model of severe left ventricle volume overload

Life Sciences

Volumn 92, Issue 1, 2013, Pages 26-34

  Dhahri, Wahiba ^a   Couet, Jacques ^a   Roussel, Élise ^a   Drolet, Marie Claude ^a   Arsenault, Marie ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Cardiomyopathy; Fenofibrate; Hypertrophy; Volume overload

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; 6 PHOSPHOFRUCTOKINASE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CARNITINE PALMITOYLTRANSFERASE; CITRATE SYNTHASE; FENOFIBRATE; GLYCOLYTIC ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE REGURGITATION; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENERGY METABOLISM; ENZYME ACTIVITY; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GENE EXPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE METABOLISM; HEART OUTPUT; HEART VENTRICLE REMODELING; HEART WEIGHT; MALE; NONHUMAN; RAT;

ANIMALS; AORTIC VALVE INSUFFICIENCY; DISEASE MODELS, ANIMAL; FATTY ACIDS; FENOFIBRATE; HYPOLIPIDEMIC AGENTS; MALE; OXIDATION-REDUCTION; PHOSPHOFRUCTOKINASES; RATS; RATS, WISTAR; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84871927586     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2012.10.022     Document Type: Article

References (45)

1. M.F. Allard Energy substrate metabolism in cardiac hypertrophy Curr Hypertens Rep 6 2004 430 435
2. M.F. Allard, H.L. Parsons, R. Saeedi, R.B. Wambolt, and R. Brownsey AMPK and metabolic adaptation by the heart to pressure overload Am J Physiol Heart Circ Physiol 292 2007 H140 H148
3. M. Arsenault, E. Plante, M.C. Drolet, and J. Couet Experimental aortic regurgitation in rats under echocardiographic guidance J Heart Valve Dis 11 2002 128 134
4. P. Balakumar, A. Rohilla, and N. Mahadevan Pleiotropic actions of fenofibrate on the heart Pharmacol Res 63 2011 8 12
5. P.M. Barger, and D.P. Kelly PPAR signaling in the control of cardiac energy metabolism Trends Cardiovasc Med 10 2000 238 245
6. P.M. Barger, J.M. Brandt, T.C. Leone, C.J. Weinheimer, and D.P. Kelly Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth J Clin Invest 105 2000 1723 1730
7. J. Berger, and D.E. Moller The mechanisms of action of PPARs Annu Rev Med 53 2002 409 435
8. L.L. Bieber, and M.A. Markwell Peroxisomal and microsomal carnitine acetyltransferases Methods Enzymol 71 Pt. C 1981 351 358
9. R.O. Bonow Aortic regurgitation Curr Treat Options Cardiovasc Med 2 2000 125 132
10. R.O. Bonow, E. Lakatos, B.J. Maron, and S.E. Epstein Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function Circulation 84 1991 1625 1635
11. R.O. Bonow, B.A. Carabello, C. Kanu, A.C.J. de Leon, D.P. Faxon, and M.D. Freed ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons Circulation 114 2006 e84 e231
12. A.A. Bouchard-Thomassin, D. Lachance, M.C. Drolet, J. Couet, and M. Arsenault A high fructose diet worsens eccentric left ventricular hypertrophy in experimental volume overload Am J Physiol Heart Circ Physiol 300 2011 H125 H134
13. S. Champetier, A. Bojmehrani, J. Beaudoin, D. Lachance, E. Plante, and E. Roussel Gene profiling of left ventricle eccentric hypertrophy in aortic regurgitation in rats: rationale for targeting the beta-adrenergic and renin-angiotensin systems Am J Physiol Heart Circ Physiol 296 2009 H669 H677
14. H.J. Chen, J.Z. Chen, X.X. Wang, and M. Yu PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats Zhejiang Da Xue Xue Bao Yi Xue Ban 36 2007 470 476
15. D.S. De Silva, R.M. Wilson, C. Hutchinson, P.C. Ip, A.G. Garcia, and S. Lancel Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms Am J Physiol Heart Circ Physiol 296 2009 H1983 H1993
16. Q.N. Diep, K. Benkirane, F. Amiri, J.S. Cohn, D. Endemann, and E.L. Schiffrin PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats J Mol Cell Cardiol 36 2004 295 304
17. F. Djouadi, B. Riveau, C. Merlet-Benichou, and J. Bastin Tissue-specific regulation of medium-chain acyl-CoA dehydrogenase gene by thyroid hormones in the developing rat Biochem J 324 Pt. 1 1997 289 294
18. T.A. Duhaney, L. Cui, M.K. Rude, N.K. Lebrasseur, S. Ngoy, and D.S. De Silva Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload Hypertension 49 2007 1084 1094
19. J.R. Dyck, and G.D. Lopaschuk AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol 574 2006 95 112
20. C. Fernandes-Santos, R.E. Carneiro, M.L. de Souza, M.B. Aguila, and C.A. Mandarim-De-Lacerda Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet Nutrition 25 2009 818 827
21. C. Hamilton, and E.D. Saggerson Malonyl-CoA metabolism in cardiac myocytes Biochem J 350Pt 1 2000 61 67
22. X. Hou, Y.H. Shen, C. Li, F. Wang, C. Zhang, and P. Bu PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity Biochem Biophys Res Commun 394 2010 653 659
23. M. Iglarz, R.M. Touyz, E.C. Viel, P. Paradis, F. Amiri, and Q.N. Diep Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension Hypertension 42 2003 737 743
24. Y. Irukayama-Tomobe, T. Miyauchi, Y. Kasuya, S. Sakai, K. Goto, and I. Yamaguchi Activation of peroxisome proliferator-activated receptor-alpha decreases endothelin-1-induced p38 mitogen-activated protein kinase activation in cardiomyocytes J Cardiovasc Pharmacol 44 Suppl. 1 2004 S358 S361
25. V. Labinskyy, M. Bellomo, M.P. Chandler, M.E. Young, V. Lionetti, and K. Qanud Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure J Pharmacol Exp Ther 321 2007 165 171
26. D. Lachance, S. Champetier, E. Plante, A.A. Bouchard-Thomassin, E. Roussel, and J. Couet Effects of exercise in volume overload: insights from a model of aortic regurgitation Med Sci Sports Exerc 41 2009 1230 1238
27. D. Lachance, E. Plante, A.A. Bouchard-Thomassin, S. Champetier, E. Roussel, and M.C. Drolet Moderate exercise training improves survival and ventricular remodeling in an animal model of left ventricular volume overload Circ Heart Fail 2 2009 437 445
28. N.K. Lebrasseur, T.A. Duhaney, D.S. De Silva, L. Cui, P.C. Ip, L. Joseph, and M.C. Drolet Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension Hypertension 50 2007 489 496
29. C.B. Li, X.X. Li, Y.G. Chen, C. Zhang, M.X. Zhang, and X.Q. Zhao Effects and mechanisms of PPARalpha activator fenofibrate on myocardial remodelling in hypertension J Cell Mol Med 13 2009 4444 4452
30. Q. Liang, and J.D. Molkentin Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models J Mol Cell Cardiol 35 2003 1385 1394
31. P. Lockyer, J.C. Schisler, C. Patterson, and M.S. Willis Minireview: Won't get fooled again: the nonmetabolic roles of peroxisome proliferator-activated receptors (PPARs) in the heart Mol Endocrinol 24 2010 1111 1119
32. K. Nishida, O. Yamaguchi, S. Hirotani, S. Hikoso, Y. Higuchi, and T. Watanabe p38alpha mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload Mol Cell Biol 24 2004 10611 10620
33. T. Ogata, T. Miyauchi, S. Sakai, Y. Irukayama-Tomobe, K. Goto, and I. Yamaguchi Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts Clin Sci (Lond) 103 Suppl. 48 2002 284S 288S
34. E. Plante, J. Couet, M. Gaudreau, M.P. Dumas, M.C. Drolet, and M. Arsenault Left ventricular response to sustained volume overload from chronic aortic valve regurgitation in rats J Card Fail 9 2003 128 140
35. E. Plante, M. Gaudreau, D. Lachance, M.C. Drolet, E. Roussel, and C. Gauthier Angiotensin-converting enzyme inhibitor captopril prevents volume overload cardiomyopathy in experimental chronic aortic valve regurgitation Can J Physiol Pharmacol 82 2004 191 199
36. E. Plante, D. Lachance, M. Gaudreau, M.C. Drolet, E. Roussel, and M. Arsenault Effectiveness of beta-blockade in experimental chronic aortic regurgitation Circulation 110 2004 1477 1483
37. E. Plante, D. Lachance, E. Roussel, M.C. Drolet, M. Arsenault, and J. Couet Impact of anesthesia on echocardiographic evaluation of systolic and diastolic function in rats J Am Soc Echocardiogr 19 2006 1520 1525
38. E. Plante, D. Lachance, S. Champetier, M.C. Drolet, E. Roussel, and M. Arsenault Benefits of long-term {beta}-blockade in experimental chronic aortic regurgitation Am J Physiol Heart Circ Physiol 294 2008 H1888 H1895
39. E. Plante, D. Lachance, J. Beaudoin, S. Champetier, E. Roussel, and M. Arsenault Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation Circ Heart Fail 2 2009 25 32
40. S. Purushothaman, M.M. Sathik, and R.R. Nair Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart J Cardiovasc Pharmacol 58 2011 254 262
41. M. Rose, P. Balakumar, and M. Singh Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats Pharmacology 80 2007 177 184
42. J. Sadoshima, O. Montagne, Q. Wang, G. Yang, J. Warden, and J. Liu The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy J Clin Invest 110 2002 271 279
43. N. Sambandam, G.D. Lopaschuk, R.W. Brownsey, and M.F. Allard Energy metabolism in the hypertrophied heart Heart Fail Rev 7 2002 161 173
44. M.E. Young, F.A. Laws, G.W. Goodwin, and H. Taegtmeyer Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart J Biol Chem 276 2001 44390 44395
45. A. Zendaoui, D. Lachance, E. Roussel, J. Couet, and M. Arsenault Usefulness of carvedilol in the treatment of chronic aortic valve regurgitation Circ Heart Fail 4 2011 207 213